White & Case Advises Bank Syndicate on US$8 Billion Financing for Teva Pharmaceutical Industries' US$39 Billion Acquisition of Allergan Genetics | White & Case LLP International Law Firm, Global Law Practice
White & Case Advises Bank Syndicate on US$8 Billion Financing for Teva Pharmaceutical Industries' US$39 Billion Acquisition of Allergan Genetics

White & Case Advises Bank Syndicate on US$8 Billion Financing for Teva Pharmaceutical Industries' US$39 Billion Acquisition of Allergan Genetics

Global law firm White & Case LLP has advised the bank syndicate on the US$8 billion bank financing for Teva Pharmaceutical Industries approximately US$39 billion acquisition of Allergan Generics, a merger of two of the world’s largest generic pharmaceutical manufacturers creating a new 'top ten' pharmaceutical company.

The syndicate was arranged by Bank of America Merrill Lynch, Barclays Bank plc, BNP Paribas, Citi, Credit Suisse, HSBC, Mizuho Bank, Morgan Stanley Senior Funding, Inc., RBC Capital Markets and Sumitomo Mitsui Banking Corporation.  This followed the representation by White & Case of the same arrangers under the $28.75 billion of bridge facilities in support of the Allergan Generics acquisition.

The White & Case team in London which advised on the transaction was led by partner David Becker and included partners Gavin Weir and John Cunningham with support from associates James Greene, Andrew Morris, Martin Mojzis and Benjamin Bierwirth.

Press contact
For more information, please speak to your local media contact.